Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

Abstract

OBJECTIVE:

To study the effect of trastuzumab in patients with progressive or recurrent metastatic endometrial carcinoma shown by immunohistochemistry to overexpress the HER2/neu receptor.

METHODS:

Disease progression was examined in 2 patients who met the study criteria, had c-erbB2 gene amplification by fluorescence in situ hybridization, and were treated with trastuzumab following radiation treatment and/or salvage chemotherapy.

RESULTS:

The clinical responses to trastuzumab as a single agent or in combination with chemotherapy were confirmed in both patients by serial CT scans and serum CA-125 evaluations. These patients with progressive or recurrent metastatic disease experienced relief from their symptoms and prolonged survival with no significant toxicity observed.

CONCLUSION:

Trastuzumab may be a viable therapeutic option as single agent or in combination with chemotherapy in patients with advanced, recurrent, and/or metastatic endometrial carcinomas overexpressing HER2/neu.

• Authors: Alessandro D Santin, Stefania Bellone, Juan J Roman, Jesse K McKenney, Sergio Pecorelli
• Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (Int J Gynaecol Obstet) Vol. 102 Issue 2 Pg. 128-31 (Aug 2008) ISSN: 0020-7292 [Print] United States
• PMID: 18555254 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• CA-125 Antigen
• Receptor, ErbB-2
• Trastuzumab

Topics

• Aged
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (therapeutic use)
• CA-125 Antigen (blood)
• Disease Progression
• Endometrial Neoplasms (blood, drug therapy, metabolism)
• Female
• Gene Expression Regulation, Neoplastic
• Genes, erbB-2 (physiology)
• Humans
• Immunohistochemistry
• In Situ Hybridization, Fluorescence
• Neoplasm Recurrence, Local (blood, drug therapy, metabolism)
• Receptor, ErbB-2 (metabolism)
• Trastuzumab